Antiepileptic Suxilep is recognized as a drug in short supply


Ryazan-based pharmaceutical company Skopinpharm (owned by OOO Pharmimex) has received permission to import Bayer’s original antiepileptic drug Suxilep (ethosuximide) in 250 mg capsules into the Russian Federation. The shortage of the drug has been recognized by the Ministry of Health of the Russian Federation, as Bez Retsepta Telegram Channel reported.

Two generics of Suxilep are produced by Mibe GmbH Arzneimittel, but in 2023 neither the original drug nor its generics were put into circulation in the Russian Federation.

In 2022, Russia’s Pik-Pharma announced the start of the registration procedure for a drug based on ethosuximide syrup under TN Epilexide. No accelerated registration procedure is available in the Russian Federation, so deliveries will not begin before mid-2023, as it was reported earlier.